Chapter 1: Understanding the HIV Virus – Structure and Lifecycle of HIV

Viruses are incredible organisms, distinct from all other life forms on Earth. They possess a strange, almost paradoxical nature that challenges the very definition of what it means to be living or non-living. They do not eat, move, grow, or age. They do not sense anything in their environment and remain inert outside a living cell. Viruses are the smallest of all reproducing organisms and lack cellular components. However, they excel at one thing: reproduction.

A virus is essentially a collection of chemicals like proteins, RNA, and DNA. Each of these chemicals can be separated and observed under a microscope; at this stage, they are not considered alive. But when these chemicals come together, they form a dynamic structure capable of reproduction. Replicating themselves is the sole function of viruses and their reason for existence.

Viruses exist at the boundary between life and death. They become active only when they hijack a living cell. As supreme parasites, they contribute nothing to the cell but instead take it over, turning it into a factory that produces more copies of the virus until the cell is ultimately destroyed. Viruses also mutate rapidly, faster than any other organism, giving them a dangerous advantage over vaccines.

The HIV virus is exceedingly small. To illustrate, if the HIV virus were the size of a golf ball, a car would be roughly the size of Mount Everest. It is comparable in size to the COVID-19 virus. HIV belongs to a family of viruses called retroviruses.

Components of a Virus

• Genetic Core: Contains either DNA or RNA.
• Capsid: Protein covering that, along with the core, forms the nucleocapsid.

Types of Viruses

There are two main types of viruses:

• DNA Viruses: Use chemicals in the cells they infect to produce more DNA copies of themselves and their envelope proteins.
• RNA Viruses: Use similar mechanisms to produce RNA copies and proteins.

HIV is an RNA virus but belongs to a unique group called retroviruses, which replicate through a complex mechanism. Unlike other RNA viruses, retroviruses do not simply replicate their RNA. They use an enzyme to produce DNA from RNA, integrating it into the host cell’s DNA. This allows retroviruses to:

• Remain longer in the cell, attacking slowly but persistently.
• Integrate into the cell’s nucleus, making detection and destruction harder.
• Mutate rapidly, complicating the immune system’s ability to combat it.

How HIV Enters the Immune System

HIV’s danger lies in how it quietly attacks the body, often going unnoticed until it has significantly weakened the immune system. The primary target of HIV is the CD4+ T lymphocyte, a crucial cell in managing the immune response. When HIV attacks these cells, it cripples the immune system, impairing the whole immune response.

Chapter 3: HIV Transmission

Introduction

Before discussing transmission in different scenarios, we need to understand the basic mechanisms behind how HIV is transmitted in the human body. We will review some key details that are crucial for understanding HIV transmission.

What Body Fluids Transmit HIV?

HIV is found in specific body fluids. It’s important to know which fluids are involved in its transmission to better protect yourself and others:

• Blood: The most significant carrier of HIV, with the highest concentration of the virus.
• Semen and Pre-seminal Fluids: Common vectors in sexual transmission.
• Rectal Fluids and Vaginal Secretions: Contain HIV and can be involved in transmission during unprotected sexual activity.
• Breast Milk: Infected mothers can transmit HIV to their babies through breast milk.

It’s equally important to know which fluids do not transmit HIV:

• Saliva: Contains trace amounts of HIV, but the concentration is too low for transmission.
• Sweat: Contains no HIV.
• Tears: Like sweat, tears do not contain HIV.
• Urine: Urine does not contain HIV.

Barriers Against Fluids

The body has two main barriers to protect against infected fluids: skin and mucous membranes, though they differ in protection levels.

• Skin: An excellent barrier against HIV, as the virus cannot penetrate intact skin.
• Mucous Membranes: These are thinner and more susceptible to microabrasions, which can allow HIV to enter during sexual activity.

How HIV Penetrates Skin and Mucous Membranes

HIV enters the body when infected fluids find an opening to the bloodstream through skin or mucous membranes.

• Transmission can occur through cuts or wounds on the skin.
• In mucous membranes, transmission is easier as infected fluids, such as semen or vaginal secretions, come into contact with microscopic tears.

Once HIV reaches the mucous membranes, it binds to cells beneath the membrane that have CD4 receptors and co-receptors like CCR5 or CXCR4, enabling viral entry and replication.

Real-World vs. Lab Conditions

It’s important to differentiate between real-world and lab studies. In real-world conditions, HIV loses infectivity within minutes on surfaces, but in labs, it can be revived under special conditions for up to 6 days. Lab findings should not be confused with real-life situations.

Non-Sexual Contact

HIV transmission through surfaces, such as towels or commodes, is virtually impossible…

Chapter 4: HIV Testing

This chapter provides a comprehensive overview of HIV testing. HIV testing has come a long way since the early days of the virus. HIV was first identified as the cause of AIDS in 1983, but it wasn’t until 1985 that the first HIV test (ELISA) became available. During those two years, the virus continued to spread unchecked due to the lack of diagnostic tools. Since then, testing has advanced significantly, with modern options like NAT tests, rapid tests, and home tests now available.

The Western blot test, a more confirmatory test, was developed in the late 1980s. In the 1990s, combo tests were introduced, and NAT tests became available in the 2000s. Rapid antibody tests first appeared in the 1990s, with rapid combo tests following in the 2000s.

Types of Tests: 1st Gen to 5th Gen and RNA Tests

HIV tests can be classified into three broad categories based on their development: antibody tests, antigen-antibody combo tests, and nucleic acid tests (NAT). Here’s an overview:

• First Generation Antibody Tests (1985): Detected IgG antibodies, but had a long window period and high false-positive rate.
• Second Generation Antibody Tests (Late 1980s): Improved accuracy, detected HIV-2, reduced false positives.
• Third Generation Antibody Tests (1990s): Detected IgM antibodies, reducing the window period to around 3 weeks.
• Fourth Generation Antigen-Antibody Tests (Late 1990s): Detected both antibodies and p24 antigen, reducing the window period to 18–45 days.
• Fifth Generation Antigen-Antibody Tests (Early 2000s): Separated antigen and antibody results, aiding in identifying recent infections.
• Nucleic Acid Amplification Tests (NAT)/RNA Tests (Early 2000s): Provided the earliest detection of HIV RNA, often within 10 days of exposure.

Methods Behind the Tests

Immunoassay

Immunoassay is the fundamental technique used in most HIV tests. This approach uses a test antibody to bind with a specific antigen, resulting in a detectable change that indicates the presence of HIV.

Chapter 5: Symptoms of HIV/AIDS: A Comprehensive Overview

Stages of HIV Infection

HIV infection typically progresses through three main stages:

• Acute HIV infection (ARS)
• Latent stage
• AIDS

Acute HIV Infection: A Detailed Look at the Symptoms

Acute HIV infection, also known as Acute Retroviral Syndrome (ARS), is the first stage of HIV infection. Symptoms in this stage result from the interaction between HIV and the immune system, occurring around 2 to 4 weeks after exposure.

Common Symptoms of Acute HIV Infection

• Fever: 80-90%
• Fatigue: 70-90%
• Headache: 50-70%
• Muscle aches and joint pain: 50-70%
• Sore throat: 50-70%
• Swollen lymph nodes: 50-70%
• Rash: 40-80%
• Nausea, vomiting, or diarrhea: 30-60%
• Night sweats: 30-50%
• Mouth ulcers: 20-40%

Fever in Acute Retroviral Syndrome (ARS)

Fever is a hallmark symptom of acute HIV infection, typically presenting as a low-grade to moderate fever. Characteristics of ARS fever include:

• Onset: Appears within 2-4 weeks post-exposure but may vary.
• Duration: Lasts from a few days to weeks, subsiding as the immune system gains control.
• Pattern: Can be intermittent or continuous.
• Severity: Varies from mild to pronounced.

Chapter 6: The Epidemiology of HIV

The Beginning of HIV

Human Immunodeficiency Virus (HIV) has profoundly impacted the world since its discovery. Understanding its origins, transmission, and sociocultural implications is essential. This chapter traces the history of HIV from its initial discovery to current understanding and treatment.

Discovery of HIV

In 1983, researchers at the Pasteur Institute in France identified a new retrovirus in lymph nodes of an AIDS patient. They named it Lymphadenopathy-Associated Virus (LAV). Around the same time, Dr. Robert Gallo’s team in the United States discovered the same virus, naming it Human T-cell Lymphotropic Virus-III (HTLV-III). These independent discoveries were crucial, confirming the link between this retrovirus and AIDS and leading to the development of diagnostic tests and treatments.

The Origin of HIV: “A Monkey Business”

HIV likely originated from Simian Immunodeficiency Virus (SIV), a virus found in non-human primates. Transmission to humans may have occurred through contact with blood while hunting or butchering infected animals, particularly chimpanzees and sooty mangabey monkeys. HIV-1 likely originated from chimpanzees in Central Africa, while HIV-2 is associated with sooty mangabeys in West Africa.

Initial Views and Misconceptions about HIV/AIDS

In its early years, HIV/AIDS was mistakenly thought to affect only specific groups. Initial names like “Gay-Related Immune Deficiency” (GRID) contributed to stigma and misinformation. Eventually, it was recognized that HIV could infect anyone, regardless of sexual orientation or other factors. This led to the coining of the term “Acquired Immunodeficiency Syndrome” (AIDS) in 1982.

Chapter 7: HIV Treatment – PrEP, PEP, ART, and Advances

Introduction

HIV treatment has advanced significantly since the challenging times of the 1980s and ’90s. What was once considered a fatal diagnosis has evolved into a manageable chronic condition for many. The landscape has shifted from one of fear and despair to one of hope and resilience.

The cornerstone of this transformation is antiretroviral therapy (ART). While not a cure, these medications effectively suppress the virus’s replication, allowing the immune system to recover and fight back. However, ART is not the only tool in our arsenal. Pre-exposure prophylaxis (PrEP) is available for those at higher risk of HIV, and post-exposure prophylaxis (PEP) can be administered in emergencies. Ongoing research continually pushes the boundaries of treatment, with promising avenues such as long-acting injectables and gene editing on the horizon.

Pre-Exposure Prophylaxis (PrEP): A Proactive Approach to HIV Prevention

Pre-exposure prophylaxis, commonly known as PrEP, is a significant advancement in HIV prevention. First approved by the U.S. Food and Drug Administration (FDA) in 2012, PrEP involves the daily administration of antiretroviral medications to substantially reduce the risk of acquiring HIV.

Mechanism of Action of PrEP

PrEP acts as a proactive defense against HIV by employing antiretroviral drugs that disrupt the virus’s lifecycle at crucial stages. The antiretroviral drugs used in PrEP primarily target two key enzymes:

• Reverse Transcriptase Inhibitors (RTIs): Block the enzyme reverse transcriptase, preventing HIV from integrating its genetic material into the host cell’s DNA.
• Integrase Inhibitors (INSTIs): Inhibit the enzyme integrase, preventing the virus from establishing a permanent infection.

Approved PrEP Medications

PrEP options vary in dosage and administration, including twice-daily, single-dose, and injectable forms. It’s essential to consult a healthcare provider to determine the most suitable PrEP regimen for your specific needs.

Indications for Pre-Exposure Prophylaxis (PrEP)

PrEP is specifically designed for individuals at higher risk of HIV infection, including those with sexual partners who are HIV-positive and not virally suppressed.

Chapter 8: The Journey Through HIV: Advances and Future Trends

Looking ahead, the future of HIV is filled with both hope and challenges. Advances in treatment have turned HIV into a manageable chronic condition, and ongoing research is working towards effective vaccines and new strategies for management and potential cures. This chapter explores these developments and what they mean for the future.

The Future of the HIV Virus

HIV’s future is a topic of scientific interest and speculation. The virus’s high mutation rate aids it in evading immune responses but could potentially lead to attenuated (less harmful) forms over time. However, HIV’s complex interaction with the immune system complicates predictions.

Advances in Treatments and Vaccines

Research is progressing in three primary areas in the fight against HIV: improving ART treatments, developing functional cure strategies, and creating vaccines.

Advancements in ART

• ART Drugs: Research is ongoing for new drugs, including two-drug regimens and promising drugs like Islatravir, Lenacapavir, and GS-9131.
• Injectable ART: Monthly or less frequent long-acting injectables are being developed, reducing the need for daily adherence.

Functional Cure Strategies

Unlike ART, functional cure strategies aim to clear HIV from the body entirely. Key strategies include:

• “Kick and Kill” Approach: Involves activating latent HIV to make it vulnerable to ART or immune responses.
• Gene Therapy: Gene editing technologies like CRISPR/Cas9 modify the immune system or HIV-infected cells to resist HIV.

A significant focus of genetic research is the CCR5 gene, which produces a protein that HIV uses to enter cells. Some individuals have a natural mutation, CCR5-Delta 32, which provides immunity to HIV. Research on this gene is ongoing, including attempts to induce the mutation through CRISPR.